OR WAIT null SECS
March 17, 2025
Video
Furie shared how Obinutuzumab could enrich the treatment landscape of LN.
March 06, 2025
Article
The rheumatology month in review emphasizes new research in gout, fibromyalgia, and lupus.
March 05, 2025
The filing acceptance is based on positive data from the phase 3 REGENCY study. A decision on the approval is expected by October 2025.
February 21, 2025
Furie discussed topline data from the REGENCY trial and key secondary endpoints.
February 14, 2025
Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.
February 07, 2025
Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.
February 05, 2025
ADI-001 now has FDA Fast Track Designation for relapsed/refractory lupus nephritis and systemic lupus erythematosus with extrarenal involvement.
December 31, 2024
Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.
December 05, 2024
Women who gave birth after infertility without receiving fertility treatments had an elevated risk of developing SARDs, such as lupus.
December 03, 2024
The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.
